INDIVIDUALS BORN IN AREAS OF HIGH* OR INTERMEDIATE† PREVALENCE RATES FOR HBV INCLUDING IMMIGRANTS AND ADOPTED CHILDREN‡§
All countries of Asia, Africa, South Pacific Island, Eastern Europe (except Hungary)
Middle East (except Cyprus and Israel)
European Mediterranean: Malta and Spain
The Arctic (indigenous populations of Alaska, Canada, and Greenland)
South America: Ecuador, Guyana, Suriname, Venezuela, and Amazon regions of Bolivia, Brazil, Colombia, and Peru
Caribbean: Antigua and Barbuda, Dominica, Granada, Haiti, Jamaica, St. Kitts and Nevis, St. Lucia, Turks and Caicos
Central America: Guatemala and Honduras
OTHER GROUPS RECOMMENDED FOR SCREENING
U.S. born persons not vaccinated as infants whose parents were born in regions with high HBV endemicity (>8%)
Household and sexual contacts of HBsAg-positive persons§
Persons who have ever injected drugs§
Persons with multiple sexual partners or history of sexually transmitted disease§
Men who have sex with men§
Inmates of correctional facilities§
Individuals with chronically elevated ALT or AST§
Individuals infected with HCV or HIV§
Patients undergoing renal dialysis§
All pregnant women
Persons needing immunosuppressive therapy
Footnotes Table 4: *HBsAg prevalence>8%; †HBsAg prevalence 2%-7%; ‡If HBsAg-positive persons are found in the first generation, subsequent generations should be tested; §Those who are seronegative should receive hepatitis B vaccine.
Table 4: Groups at high risk for HBV infection who should be screened prior to anti-TNF therapy (adapted from AASLD practice guidelines updated).
 
Goto home»